Patents by Inventor Thomas William Rademacher
Thomas William Rademacher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9125583Abstract: The use of nanoparticles for imaging a tumor in a mammal using electrical impedance tomography. The nanoparticles comprise a core of metal and/or semiconductor atoms to which are linked ligands that comprise a molecule capable of attaching to a specific tumor biomarker.Type: GrantFiled: November 6, 2009Date of Patent: September 8, 2015Assignees: Middlesex University Higher Education Corporation, Midatech LimitedInventors: Richard Harold Bayford, Ivan Maurice Roitt, Thomas William Rademacher, Andreas Demosthenous, Raymond Kruse Iles
-
Patent number: 9079765Abstract: Nanoparticles comprising adjuvants and antigens, such as tumor and pathogen antigens, are disclosed and their use in a range of applications such as for the treatment of cancer and infectious diseases. Immunogenic structures based on nanoparticles or antibodies with carbohydrate ligands, and their use for therapeutic and prophylactic purposes, and for the isolation and detection of antibodies directed against the carbohydrate structures.Type: GrantFiled: September 30, 2005Date of Patent: July 14, 2015Assignee: Midatech Ltd.Inventors: Gottfried Himmler, G. C. Mudde, Ralf Kircheis, Thomas William Rademacher, Soledad Penades Ullate, Manuel Martin Lomas, Jose Luis De Paz Carrera, Rafael Ojeda Martinez De Castilla, Africa Garcia Barrientes
-
Patent number: 9034380Abstract: Materials and Methods are disclosed for producing nanoparticles linked to antibacterial ligands, including antibiotics and/or molecules which bind to bacterial markers, and for the use of the nanoparticles for the treatment of conditions treatable by the antibiotic ligands.Type: GrantFiled: August 4, 2006Date of Patent: May 19, 2015Assignee: Midatech Ltd.Inventors: Thomas William Rademacher, Godfrey Bradman, Soledad Penades Ullate, Rafael Ojeda Martinez De Castilla
-
Patent number: 8895023Abstract: Nanoparticles for providing immune responses for the treatment or prophylaxis of infection by infectious agents such as viruses, parasites, bacteria, prions and fungi are described which comprises a core including metal and/or semiconductor atoms, wherein the core is covalently linked to a plurality of ligands, the ligands including a carbohydrate residue capable of stimulating an innate immune response, a T cell helper peptide and a danger signal. This platform may then be adapted by including one or more further ligands capable of producing a specific response to a target infectious agent.Type: GrantFiled: April 22, 2013Date of Patent: November 25, 2014Assignee: Midatech LimitedInventors: Thomas William Rademacher, Phillip Williams
-
Publication number: 20140107738Abstract: Materials and methods for making small magnetic particles, e.g., clusters of metal atoms, which can be employed as a substrate for immobilizing a plurality of ligands. Also disclosed are uses of these magnetic nanoparticles as therapeutic and diagnostic reagents, and in the study of ligand-mediated interactions.Type: ApplicationFiled: October 2, 2013Publication date: April 17, 2014Applicants: Midatech Limited, Consejo Superior De Investigacione CientificasInventors: Soledad Penades, Manual Martin-Lomas, Jesus Martines de la Fuente, Thomas William Rademacher
-
Patent number: 8557607Abstract: Materials and methods for making small magnetic particles, e.g. clusters of metal atoms, which can be employed as a substrate for immobilizing a plurality of ligands. Also disclosed are uses of these magnetic nanoparticles as therapeutic and diagnostic reagents, and in the study of ligand-mediated interactions.Type: GrantFiled: June 7, 2004Date of Patent: October 15, 2013Assignees: Consejo Superior de Investigacione Cientificas, Midatech LimitedInventors: Soledad Penades, Manuel Martin-Lomas, Jesus Martines De La Fuente, Thomas William Rademacher
-
Patent number: 8425915Abstract: Nanoparticles for providing immune responses for the treatment or prophylaxis of infection by infectious agents such as viruses, parasites, bacteria, prions and fungi are described which comprises a core including metal and/or semiconductor atoms, wherein the core is covalently linked to a plurality of ligands, the ligands including a carbohydrate residue capable of stimulating an innate immune response, a T cell helper peptide and a danger signal. This platform may then be adapted by including one or more further ligands capable of producing a specific response to a target infectious agent.Type: GrantFiled: April 13, 2007Date of Patent: April 23, 2013Assignee: Midatech LimitedInventors: Thomas William Rademacher, Philip Williams
-
Publication number: 20110212029Abstract: The use of nanoparticles for imaging a tumour in a mammal using electrical impedance tomography. The nanoparticles comprise a core of metal and/or semiconductor atoms to which are linked ligands that comprise a molecule capable of attaching to a specific tumour biomarker.Type: ApplicationFiled: November 6, 2009Publication date: September 1, 2011Inventors: Richard Harold Bayford, Ivan Maurice Roitt, Thomas William Rademacher, Andreas Demosthenous, Raymond Kruse Iles
-
Publication number: 20090297614Abstract: Nanoparticles for providing immune responses for the treatment or prophylaxis of infection by infectious agents such as viruses, parasites, bacteria, prions and fungi are described which comprises a core including metal and/or semiconductor atoms, wherein the core is covalently linked to a plurality of ligands, the ligands including a carbohydrate residue capable of stimulating an innate immune response, a T cell helper peptide and a danger signal. This platform may then be adapted by including one or more further ligands capable of producing a specific response to a target infectious agent.Type: ApplicationFiled: April 13, 2007Publication date: December 3, 2009Inventors: Thomas William Rademacher, Philip Williams
-
Publication number: 20090181101Abstract: Materials and Methods are disclosed for producing nanoparticles linked to antibacterial ligands, including antibiotics and/or molecules which bind to bacterial markers, and for the use of the nanoparticles for the treatment of conditions treatable by the antibiotic ligands.Type: ApplicationFiled: August 4, 2006Publication date: July 16, 2009Inventors: Thomas William Rademacher, Godfrey Bradman, Soledad Penades Ullate, Rafael Ojeda Martinez De Castilla
-
Publication number: 20090104268Abstract: Nanoparticles comprising adjuvants and antigens, such as tumour and pathogen antigens, are disclosed and their use in a range of applications such as for the treatment of cancer and infectious diseases. Immunogenic structures based on nanoparticles or antibodies with carbohydrate ligands, and their use for therapeutic and prophylactic purposes, and for the isolation and detection of antibodies directed against the carbohydrate structures.Type: ApplicationFiled: September 30, 2005Publication date: April 23, 2009Applicant: Midatech LimitedInventors: Gottfried Himmler, G. C. Mudde, Ralf Kircheis, Thomas William Rademacher, Soledad Penades Ullate, Manuel Martin Lomas, Jose Luis De Paz Carrera, Rafael Ojeda Martinez De Castilla, Africa Garcia Barrientes
-
Publication number: 20080213177Abstract: Materials and methods are provided for making nanoparticles having a core including metal and/or semiconductor atoms, which core is covalently linked to a plurality of ligands comprising a RNA ligand. The RNA ligands may include siRNA or miRNA. Also provided are uses of these nanoparticles in therapy and diagnosis.Type: ApplicationFiled: May 24, 2005Publication date: September 4, 2008Inventors: Thomas William Rademacher, Manuel Martin-Lomas, Soledad Penades, Rafael Ojeda, African G. Barrientes, Khalid Gumaa
-
Patent number: 7235533Abstract: Compounds having a mimetic or antagonistic property of an inositol phosphoglycan, and the uses of these compounds are disclosed, together with the use, e.g. to treat a condition ameliorated by administration of an IPG second messenger or an IPG antagonist thereof. In particular, the compounds are based on the 1,6 linkage of a sugar residue and a cyclitol.Type: GrantFiled: May 19, 2005Date of Patent: June 26, 2007Assignee: Rodaris Pharmaceuticals LimitedInventors: Manuel Martin-Lomas, Thomas William Rademacher, Hugo Norberto Caro, Irene Francois
-
Patent number: 6953781Abstract: Compounds having a mimetic or antagonistic property of an inositol phosphoglycan, and the uses of these compounds are disclosed, together with the use, e.g. to treat a condition ameliorated by administration of an IPG second messenger or an IPG antagonist thereof. In particular, the compounds are based on the 1,6 linkage of a sugar residue and a cyclitol.Type: GrantFiled: March 2, 2001Date of Patent: October 11, 2005Assignee: Rodaris Pharmaceuticals LimitedInventors: Manuel Martin-Lomas, Thomas William Rademacher, Hugo Norberto Caro, Irene Francois
-
Patent number: 6939857Abstract: Compounds having a mimetic or antagonistic property of an inositol phosphoglycan, and the uses of these compounds are disclosed, together with the use, e.g. to treat a condition ameliorated by administration of an IPG second messenger or an IPG antagonist thereof. Preferred compounds of the invention are based on the substituted cyclitols, such as the chiro-inositol derivative pinitol (3-O-methyl-chiro-inositol).Type: GrantFiled: March 2, 2001Date of Patent: September 6, 2005Assignee: Rodaris Pharmaceuticals LimitedInventors: Manuel Martin-Lomas, Thomas William Rademacher, Hugo Norberto Caro, Irene Francois
-
Patent number: 6900182Abstract: Compositions comprising inositolphosphoglycans (IPGs) and ribose are disclosed, and their use in the prevention or treatment of ischaemic-reperfusion injury. This treatment increases the energy generating systems of cells by employing the mitochondrial oxidative restoration system. The use of the compositions in preserving organs for transplantation is also disclosed.Type: GrantFiled: May 12, 1999Date of Patent: May 31, 2005Assignee: Sylus Pharmaceuticals Ltd.Inventors: Thomas William Rademacher, Leslie Greenbaum, Patricia McLean
-
Publication number: 20040192586Abstract: The present invention relates to anti-IPG antibodies, and in particular monoclonal antibodies produced by hybridoma cell lines 2F7. 2D1 and 5H6, and the use of these and other similar antibodies in the treatment and diagnosis of pre-eclampsia or diabetes, especially type I diabetes. A method of producing anti-IPG antibodies by immunising an animal with IPG unconjugated to an immunogenic carrier is also disclosed.Type: ApplicationFiled: April 1, 2004Publication date: September 30, 2004Applicant: Rodaris Pharmaceuticals LimitedInventors: Varela-Nieto Isabel, Jose Mato, Jesus Prieto, Phillip Williams, Thomas William Rademacher
-
Publication number: 20040167064Abstract: The present invention relates to use of GPI-PLD antagonists for the prevention, treatment and diagnosis of pre-eclampsia. The substantial GPI-PLD activity is present in the placenta in pre-eclampsia is not expressed in the placenta, but rather is taken up from the material circulation. As a result, abnormal or dysregulated GPI-PLD activity present in the placenta in pre-eclampsia may be correctable by administration of GPI-PLD to the mother to correct the problems caused by abnormal or dysregulated GPI-PLD, e.g. to reduce the abnormal release and in situ production of placental IPGs involved in the pathogenesis of pre-eclampsia. This can be achieved using exogenous GPI-PLD or a fragment thereof, e.g. an inactive GPI-PLD capable of competing with or displacing the abnormal or dysregulated GPI-PLD, e.g. from Apo-A1.Type: ApplicationFiled: May 1, 2003Publication date: August 26, 2004Inventors: Julian Schofield, Thomas William Rademacher, Sylvie Deborde
-
Publication number: 20040141973Abstract: This application discloses that inositolphosphoglycans (IPGs) can be obtained from basophils, eosinophils and mast cells and that allergen stimulation of these cells results in IPG release. It also shows that IPGs are second messengers for allergic stimulation as the addition of some types of purified IPGs to non-allergen stimulated cells resulted in histamine release or degranulation. Thus, IPG antagonists can be used for the treatment of conditions (especially allergy and asthma) mediated by the release of IPGs from mast cells, basophils or eosinophils. Preferred IPG antagonists include anti-IPG antibodies, inhibitors of the enzyme GPI-PLD and competitive antagonists.Type: ApplicationFiled: December 11, 2003Publication date: July 22, 2004Applicant: University College LondonInventors: Thomas William Rademacher, Helen Whitby
-
Patent number: 6759390Abstract: Compounds having a mimetic or antagonistic property of an inositol phosphoglycan, and the uses of these compounds are disclosed, together with the use, e.g. to treat a condition ameliorated by administration of an IPG second messenger or an IPG antagonist thereof. Preferred compounds of the invention are based on the substituted cyclitols, and in particular cyclitols linked to a sugar moiety where the molecule is substituted with a negatively charged group such as phosphate.Type: GrantFiled: March 2, 2001Date of Patent: July 6, 2004Inventors: Manuel Martin-Lomas, Thomas William Rademacher, Hugo Norberto Caro, Irene Francois